268
Views
13
CrossRef citations to date
0
Altmetric
Research Article

Formulation Design of a Highly Hygroscopic Drug (Pyridostigmine Bromide) for its Hygroscopic Character Improvement and Investigation of In Vitro/In Vivo Dissolution Properties

, , , , &
Pages 403-416 | Published online: 26 Sep 2008
 

ABSTRACT

Pyridostigmine bromide (PB) sustained-release (SR) pellets were developed by extrusion-spheronization and fluid-bed methods using Taguchi experimental and 23 full factorial design. In vitro studies, the 23 full factorial design was utilized to search for the optimal SR pellets with specific release rate at different time intervals (release percent of 2, 6, 12, and 24 hr were 6.24, 33.48, 75.18, and 95.26%, respectively) which followed a zero-order mechanism (n = 0.93). The results of moisture absorption by Karl Fischer has shown the optimum SR pellets at 25°C/60% RH, 30°C/65% RH, and 40°C/75% RH chambers from 1 hr–4 weeks, attributing that the moisture absorption was not significantly increased. In the in vivo study, the results of the bioavailability data showed the Tmax (from 0.65 ± 0.082 hr–4.82 ± 2.12 hr) and AUC0–30 hr (from 734.88 ± 230.68 ng/mL.hr–1454.86 ± 319.28 ng/mL.hr) were prolonged and increased, as well as Cmax (from 251.87 ± 27.51 ng/mL–115.08 ± 14.87 ng/mL) was decreased for optimum SR-PB pellets when compared with commercial immediate-release (IR) tablets. Furthermore, a good linear regression relationship (r = 0.9943) was observed between the fraction dissolution and fraction absorption for the optimum SR pellets. In this study, the formulation design not only improved the hygroscopic character of PB but also achieved the SR effect.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.